



Monica Seles to front Shire's binge eating disorder campaign

Tennis star experienced condition at height of her success



Pharma company Shire has enlisted multi-Grand Slam winning tennis star Monica Seles to support its campaign to raise awareness of binge eating disorder in adults in the US.

Shire and Seles will work with charities the Binge Eating Disorder Association (BEDA) and the National Eating Disorders Association (NEDA) to motivate adults with symptoms of binge eating disorder to learn more about the condition and talk to a healthcare professional.

Seles recently admitted to experiencing binge eating disorder when she was a professional tennis player in the 1990s.

"There is a misconception that adults with binge eating disorder fit a certain profile," said Seles. "I felt ashamed about my binge eating for so long, and my hope is that hearing the stories of people like me, and having information about the disorder more publicly available, may help inspire other adults to get the support they need."

Binge eating disorder is one of the most common mental health conditions in the US, affecting around 2.8 million adults in the US. It is characterised by regularly eating far more food than most people would eat in a similar time period, with binges taking place on at least a weekly basis for three months.


As part of the campaign the partners have created the website www.bingeeatingdisorder.com, which features further details of Seles' story as well as information about the condition, such as symptoms, potential causes and tips for how to raise the topic with loved ones and healthcare providers.

Shire recently won the first approval in the US for a medicine to help people with binge eating disorder with FDA backing for **Vyvanse** (lisdexamfetamine dimesylate).

The new indication for the drug, which is already used to treat attention-deficit hyperactivity disorder (ADHD), is expected to boost sales by around \$500m a year.

Vyvanse's efficacy in the treatment of binge eating was shown in two clinical trials that included 724 adults with moderate-to-severe symptoms of the disorder, according to the FDA.

In the studies, participants taking Vyvanse experienced a decrease in the number of binge eating days per week and had fewer obsessive-compulsive binge eating behaviours compared to those on placebo.



Be the first to comment.

ALSO ON PMLIVE

FDA slams Kardashian West's Instagram drug promotion

1 comment • a year ago•



Paul Jackson — I despair of the idiocy of people sometimes. Taking advice on medication while pregnant from an ...

Time to get personal about adherence

1 comment • 2 years ago •



Hanno Wolfram — A chronic diagnosis is where I believe fostering adherence is most necessary. Questions: Could it be, that a ...

Frontera supports unique fashion auction for homeless charity

1 comment • a year ago•



RoughSleeper - Thankyou Vivian. One of the few genuine people looking out for us, when so many homeless charities are ...

Limited access to new hep C treatments under the spotlight

1 comment • a year ago•



Marowincyin — The prices truly are staggering. I really wanted to see Daklinza vs Sovaldi for genotype 3. Sovaldi is very ...









